

file

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Attorney Docket No.: 20093A-002100US		Application No.: 09/301,380	
		Applicant: Gerald P. Murphy, <i>et al.</i>			
		Filing Date: June 15, 2001		Group: 1635	
Reference Designation		U.S. PATENT DOCUMENTS			
Page 1 of 1					

Examiner Initial	Document	Name	Class	Sub-class	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
<u>mmS</u> AA	✓ Schwab, G. <i>et al.</i> , <i>An Approach for New Anticancer Drugs: Oncogene-Targeted Antisense DNA</i> , <u>Annals of Oncology</u> 5:55-58, 1994.
<u>mmS</u> AB	✓ Matveeva, O. <i>et al.</i> , <i>A Rapid In Vitro Method For Obtaining RNA Accessibility Patterns For Complementary DNA Probes: Correlation With An Intracellular Pattern and Known RNA Structures</i> , <u>Nucleic Acids Res.</u> 25:5010-6, 1997.
<u>mmS</u> AC	✓ Flanagan, Michael W., <i>Antisense Comes of Age</i> , <u>Cancer and Metastasis Reviews</u> 17:169-176, 1998.
<u>mmS</u> AD	✓ Ho, Siew Peng <i>et al.</i> , <i>Antisense Oligonucleotides for Target Validation in the CNS</i> , <u>Current Opinion in Molecular Therapeutics</u> 1:336-343, 1999.
<u>mmS</u> AE	✓ Holmlund, Jon T <i>et al.</i> , <i>Toward Antisense Oligonucleotide Therapy for Cancer: ISIS Compounds in Clinical Development</i> , <u>Current Opinion in Molecular Therapeutics</u> 1:372-385, 1999.
___ AF	
___ AG	
___ AH	
___ AI	
___ AJ	
___ AK	
___ AL	
___ AM	
___ AN	

EXAMINER <i>mm Schmidt</i>	DATE CONSIDERED <i>8/25/02</i>
----------------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 5012889v1